- Home
- DGICB vs ANNX Comparison
DGICB vs ANNX Comparison
Compare DGICB & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICB
- ANNX
- Stock Information
- Founded
- DGICB 1986
- ANNX 2011
- Country
- DGICB United States
- ANNX United States
- Employees
- DGICB N/A
- ANNX N/A
- Industry
- DGICB Property-Casualty Insurers
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- DGICB Finance
- ANNX Health Care
- Exchange
- DGICB Nasdaq
- ANNX Nasdaq
- Market Cap
- DGICB 504.0M
- ANNX 540.4M
- IPO Year
- DGICB N/A
- ANNX 2020
- Fundamental
- Price
- DGICB $15.06
- ANNX $4.88
- Analyst Decision
- DGICB
- ANNX Strong Buy
- Analyst Count
- DGICB 0
- ANNX 7
- Target Price
- DGICB N/A
- ANNX $15.80
- AVG Volume (30 Days)
- DGICB 928.0
- ANNX 1.4M
- Earning Date
- DGICB 10-24-2024
- ANNX 11-14-2024
- Dividend Yield
- DGICB 4.12%
- ANNX N/A
- EPS Growth
- DGICB 148.60
- ANNX N/A
- EPS
- DGICB 0.74
- ANNX N/A
- Revenue
- DGICB $979,119,004.00
- ANNX N/A
- Revenue This Year
- DGICB N/A
- ANNX N/A
- Revenue Next Year
- DGICB $5.78
- ANNX N/A
- P/E Ratio
- DGICB $21.91
- ANNX N/A
- Revenue Growth
- DGICB 7.44
- ANNX N/A
- 52 Week Low
- DGICB $10.75
- ANNX $2.75
- 52 Week High
- DGICB $16.81
- ANNX $8.40
- Technical
- Relative Strength Index (RSI)
- DGICB 59.65
- ANNX 38.39
- Support Level
- DGICB $14.26
- ANNX $4.40
- Resistance Level
- DGICB $15.90
- ANNX $5.30
- Average True Range (ATR)
- DGICB 0.53
- ANNX 0.31
- MACD
- DGICB -0.02
- ANNX 0.03
- Stochastic Oscillator
- DGICB 31.38
- ANNX 41.74
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.